Aurora Cannabis (ACB) Gross Margin (2017 - 2026)
Aurora Cannabis (ACB) posted quarterly Gross Margin of 25.61% for Q1 2026, up 663.0% year-on-year from 3.36% in Q1 2025, and down 36.5% on a QoQ basis from 40.33% in Q4 2025.
Aurora Cannabis (ACB) Gross Margin (2017 - 2026) Analysis & Trends
Aurora Cannabis (ACB) has reported Gross Margin for 10 consecutive years, with 25.61% the latest figure, recorded in Q1 2026.
- Quarterly Gross Margin rose 663.0% year-over-year to 25.61% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 32.48% (up 31412.0% YoY) and the FY2026 annual result came in at 42.62%, down 2001.0% from the prior year.
- Gross Margin retreated to 25.61% in Q1 2026 per ACB's latest filing, from 40.33% in the prior quarter.
- Over the last five years, Gross Margin for ACB reached as high as 252.76% in Q2 2024 and fell as low as 1464.34% in Q3 2024.
- A 5-year average of 142.36% and a median of 22.3% in 2026 frame the typical range for Gross Margin.
- Annual changes were most pronounced in 2024 — Gross Margin sank 107866 bps — and 2025, when it surged 150007 bps.
- Year by year, Gross Margin stood at 8.02% in 2022, then surged by 584 bps to 38.81% in 2023, then surged by 119 bps to 84.96% in 2024, then slumped by 53 bps to 40.33% in 2025, then tumbled by 36 bps to 25.61% in 2026.
- According to Business Quant data, Gross Margin over the past three periods registered 25.61%, 40.33%, and 35.73% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 49.52% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 71.66% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 62.93% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 82.93% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 32.97% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 98.31% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 57.26% |
| 10 | Aurora Cannabis | 1.11 Bn | 1.03 Bn | 21.72 Mn | 25.61% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 25.61% |
| Dec 31, 2025 | 40.33% |
| Sep 30, 2025 | 35.73% |
| Jun 30, 2025 | 28.51% |
| Mar 31, 2025 | 18.98% |
| Dec 31, 2024 | 84.96% |
| Sep 30, 2024 | -1,464.34% |
| Jun 30, 2024 | 252.76% |
| Mar 31, 2024 | 68.72% |
| Dec 31, 2023 | 38.81% |
| Sep 30, 2023 | -385.68% |
| Jun 30, 2023 | -1,009.21% |
| Dec 31, 2022 | -8.02% |
| Sep 30, 2022 | 8.96% |
| Jun 30, 2022 | 14.23% |
| Mar 31, 2022 | -28.13% |
| Dec 31, 2021 | 9.21% |
| Sep 30, 2021 | 42.34% |
| Jun 30, 2021 | -10.56% |
| Mar 31, 2021 | -154.93% |